

Our goal is to empower PI patients and caregivers—so everyone can better understand and manage treatments while also helping to connect the broader PI community, advance PI research, and protect our environment.



This is just one more way IgCares is showing our patients and the world that we care about PI and the people it affects.

To access unequalled PI education and support, join our program on the **IgCares app, at [IgCares.com](https://www.IgCares.com), or call 1-833-382-7686.**



Scan to download
the IgCares App

IMPORTANT SAFETY INFORMATION FOR CUTAQUIG

Warnings and Precautions (Continued)

Non-cardiogenic pulmonary edema may occur in patients administered human immune globulin products. Monitor for pulmonary adverse reactions. If transfusion-related acute lung injury is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient's serum. Cutaquig is made from human plasma and may carry a risk of transmitting infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Drug Interactions

After infusion of cutaquig, the transitory rise of the various passively transferred antibodies in the patient's blood may yield false positive serological test results, with the potential for misleading interpretation.

Adverse Reactions

The most common adverse reactions ($\geq 5\%$ of study subjects) were local infusion site reactions (such as redness, swelling, itching), headache, fever, diarrhea, dermatitis, asthma, and skin abrasion.



Full-circle Support for the
Primary Immunodeficiency (PI) Community

octapharma®

For the safe and optimal use of human proteins

©2020, Octapharma USA Inc. All rights reserved.
Date of preparation: 10/2020. CUTA-0282-PRC



Welcome to a New Type of Patient Support Program

IgCares is here for you—with a best-in-class primary immunodeficiency (PI) patient support program from Octapharma. In addition to providing education and treatment resources to PI patients and caregivers, our comprehensive program also benefits the PI community as well as your planet.

INDICATIONS AND USAGE

Cutaquig® (Immune Globulin Subcutaneous (Human) – hipp) is a 16.5% immune globulin solution for subcutaneous infusion indicated for treatment of primary humoral immunodeficiency (PI) in adults. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

- Thrombosis may occur with immune globulin products, including CUTAQUIG. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. [see Warnings and Precautions (5.2), Patient Counseling Information (17)]
- For patients at risk of thrombosis, administer CUTAQUIG at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. [see Warnings and Precautions (5.2)]

Your Needs and Priorities Inspired the IgCares Program

IgCares is a dynamic experience that reflects your needs, your preferences, and where you are in your PI journey.

To join our community and access our highly innovative support initiatives, simply download the **IgCares app** at **IgCares.com** or call **1-833-382-7686**.

In an effort to ensure the broadest reach possible, IgCares is widely accessible to any adult in the US who would like to join.*

The IgCares program is designed to inspire you with initiatives, including:



*Certain components of the IgCares patient support program are available only for adult patients who are using or have a prescription for an Octapharma subcutaneous immunoglobulin product for the treatment of primary immunodeficiency.



Care for your self

Discover a wide range of best practices, tips, and tools to succeed in your PI treatment journey

The IgCares program gives you access to individualized educational content and informational resources that can help you better understand and manage the steps, timing, and details specific to your PI treatment.

To stay in step with your treatment journey, we continually update your educational materials.

It's all part of knowing your options to maintain and improve your overall well-being.



IMPORTANT SAFETY INFORMATION FOR CUTAQUIG

Contraindications

Cutaquig® is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the subcutaneous administration of human immune globulin or to any of the components of cutaquig such as Polysorbate 80, and in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.

Warnings and Precautions

Severe hypersensitivity reactions may occur with cutaquig, even in patients who tolerated previous treatment with human immune globulin. If a hypersensitivity reaction occurs, discontinue the cutaquig infusion immediately and initiate appropriate treatment. IgA-deficient patients with anti-IgA antibodies are at greater risk of severe reactions. Thrombosis may occur following treatment with immune globulin products, including cutaquig. For patients at risk of thrombosis, administer cutaquig at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.



Care for your spirit

Personal connections to peers, the PI community, and patient advocates

Fellowship and support can make a difference in your well-being, so IgCares helps you connect with others who understand your PI experiences.

Live support helps you:

- Ask questions and receive answers about PI and its treatments
- Investigate benefits and receive copay assistance
- Get support from an IgCares nurse advisor if you need help self-infusing

With IgCares by your side, you're never alone.



Care for your causes

Partnering to support the PI community

IgCares wants to help you support organizations dedicated to improving lives within the PI community, and it all begins by helping yourself.

Earn points every time you interact with the IgCares app. We convert your points into dollars and then you decide which IgCares participating charitable foundation or research institution should receive the support. Organizations include:

- **The Immune Deficiency Foundation:** primaryimmune.org
- **The Jeffrey Model Foundation:** info4pi.org
- **The Foundation for Primary Immunodeficiency Diseases:** fpid.org
- **International Patient Organisation for Primary Immunodeficiencies:** ipopi.org

IMPORTANT SAFETY INFORMATION FOR CUTAQUIG

Warnings and Precautions (Continued)

Falsely elevated blood glucose readings may occur during and after the infusion of cutaquig with some glucometer and test strip systems. When administering cutaquig, measure blood glucose with a glucose-specific method. Aseptic meningitis syndrome (AMS) can occur with cutaquig. AMS has been reported after the use of human immune globulin administered intravenously and subcutaneously and may occur within 2 days following treatment. Discontinuation of immunoglobulin treatment has resulted in remission within several days without sequelae. Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis and death may occur with use of human immune globulin, especially those containing sucrose. cutaquig does not contain sucrose. Monitor patients for signs and symptoms of renal dysfunction. Monitor blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure. Monitor cutaquig recipients for clinical signs and symptoms of hemolysis, particularly patients with pre-existing anemia and/or cardiovascular or pulmonary compromise. Consider appropriate confirmatory laboratory testing if signs and symptoms of hemolysis are present after cutaquig infusion.



Care for your world

Working together to protect our planet

We simplified a way to help keep waste out of our landfills and repurpose it to generate electricity. All of this can be done by simply and safely disposing of your sharps, other infusion supplies, and the packaging and shipping materials associated with your prescription.

Here is our 3-step initiative to help you go green:



1 After joining the IgCares program, you will receive a custom sharps container and a larger shipping box to hold all infusion supplies.



2 Once the sharps container is full, place it into the larger box and ship back to IgCares.



3 IgCares will then properly dispose of all materials.

You can request a new container through **IgCares app**, at **IgCares.com**, or by calling **1-833-382-7686**.